dorzolamide has been researched along with Diabetes-Mellitus--Type-1* in 2 studies
1 trial(s) available for dorzolamide and Diabetes-Mellitus--Type-1
Article | Year |
---|---|
Dilatation of Retinal Arterioles Induced by Topical Dorzolamide for One Week Is Impaired in Patients with Type 1 Diabetes and Mild Retinopathy.
Diabetic retinopathy is characterised by morphological lesions in the retina secondary to disturbances in retinal blood flow. Previous studies have shown that the carbonic anhydrase inhibitor (CAI) dorzolamide can induce immediate dilatation of retinal arterioles and a sustained increase in retinal blood flow in primary open-angle glaucoma. However, the effect of sustained treatment with CAI on retinal arterioles in normal persons and in patients with diabetic retinopathy is unknown.. The Dynamic Vessel Analyzer was used to assess the baseline diameter and the diameter response of retinal arterioles during an increase in arterial blood pressure induced by isometric exercise and during flicker stimulation before and 2 h, 24 h and 1 week after onset of topical treatment with dorzolamide. At each examination the diameter responses were studied before and during breathing in of a hypercapnic gas mixture.. Treatment with dorzolamide for 1 week significantly increased the diameter of retinal arterioles in normal persons, and breathing in of a hypercapnic gas mixture reduced this response. The pathological vasodilatation and reduced retinal autoregulation in patients with diabetic retinopathy were unaffected by dorzolamide and hypercapnia.. The study suggests a lack of relevance of CAI for the treatment of pathological vasodilatation in early diabetic retinopathy. Topics: Administration, Ophthalmic; Adult; Arterioles; Blood Pressure; Carbonic Anhydrase Inhibitors; Diabetes Mellitus, Type 1; Diabetic Retinopathy; Female; Homeostasis; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Prospective Studies; Regional Blood Flow; Retinal Artery; Sulfonamides; Thiophenes; Vasodilation | 2020 |
1 other study(ies) available for dorzolamide and Diabetes-Mellitus--Type-1
Article | Year |
---|---|
Clinical estimation of corneal endothelial pump function.
To develop a technique to estimate the corneal endothelial pump rate in human subjects.. Corneal hydration control is thought to be maintained by a pump-leak mechanism whereby the leak of solutes and fluid across the endothelial barrier into the stroma is, in the steady state, exactly balanced by the pumping of solutes and passive fluid transfer across the endothelium to the aqueous humor. Overall corneal hydration control can be measured from the rate at which the swollen cornea thins (deswells), and a measure of the leak can be obtained simultaneously from the endothelial permeability to fluorescein. From the pump-leak hypothesis, the deswelling rate is directly proportional to the pump rate and inversely proportional to the leak rate. The relative endothelial pump rate can be estimated as the product of the normalized deswelling rate and the normalized endothelial permeability. This procedure was used to obtain the relative endothelial pump rate in 41 patients with diabetes mellitus, 12 patients with long-term corneal transplants, 20 long-term wearers of contact lenses, and 19 normal volunteer subjects after the short-term administration of topical dorzolamide.. The relative endothelial pump rate did not differ significantly from that of control subjects in diabetics, in contact lens wearers, and after dorzolamide administration, but was markedly decreased in the patients with corneal transplants, despite a reduction in permeability (reduced leak).. This method allows the estimation of both the barrier and pump arms of corneal endothelial function and should be useful in the investigation of causes and mechanisms of functional endothelial insufficiency. Topics: Administration, Topical; Adolescent; Adult; Body Water; Contact Lenses; Corneal Edema; Corneal Transplantation; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Endothelium, Corneal; Humans; Permeability; Reference Values; Sulfonamides; Thiophenes | 1998 |